Related Experiment Video
Updated: Jun 16, 2026
10:18
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Idiotype vaccines for human B-cell malignancies.
S Inoges1, A Lopez-Diaz de Cerio, E Soria
1Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Current Pharmaceutical Design
|January 30, 2010
Summary
Customized idiotype vaccines show promise for B-cell malignancies like lymphoma and myeloma, demonstrating biological efficacy but facing challenges in clinical trials and regulatory approval. Future research needs improved trial designs to confirm patient benefit and gain approval.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Customized idiotype vaccination is an experimental therapy for B-cell malignancies, aiming to prevent disease recurrence.
- This approach targets B-cell malignancies expressing clonal immunoglobulin on their surface.
Purpose of the Study:
- To review the successes and challenges of idiotype vaccines in treating lymphoma and myeloma.
- To outline future directions for improving feasibility, immunogenicity, efficacy, and regulatory approval.
Main Methods:
- Review of existing clinical trial data for idiotype vaccines in lymphoma and myeloma.
- Analysis of the biological and clinical efficacy across different B-cell malignancies.
- Assessment of challenges in trial design, comparability, and patient selection.
Main Results:
- Idiotype vaccines have shown biological and clinical efficacy in follicular lymphoma, but failed to meet regulatory endpoints.
- Biological efficacy is proven in mantle cell lymphoma; limited evidence suggests biological and potential clinical efficacy in multiple myeloma.
- Varied vaccine production and administration methods hinder result comparison and meta-analysis.
Conclusions:
- Idiotype vaccines have demonstrated multifaceted success but require improved trial designs for regulatory approval.
- Identifying predictive biomarkers for patient response is crucial for future development.
- Enhancing feasibility, immunogenicity, and efficacy are key challenges for advancing idiotype vaccines.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...